Title:
MACROCYCLIC COMPOUNDS AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/240978
Kind Code:
A8
Abstract:
Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
Inventors:
HUANG WEI-SHENG (US)
SHAKESPEARE WILLIAM (US)
EYERMANN CHARLES (US)
DALGARNO DAVID (US)
SHAKESPEARE WILLIAM (US)
EYERMANN CHARLES (US)
DALGARNO DAVID (US)
Application Number:
PCT/US2022/028755
Publication Date:
October 05, 2023
Filing Date:
May 11, 2022
Export Citation:
Assignee:
THESEUS PHARMACEUTICALS INC (US)
International Classes:
C07D498/22; A61K31/395; A61P35/00
Attorney, Agent or Firm:
COLES, Anthony et al. (US)
Download PDF:
Previous Patent: SYSTEM FOR FORMING A DEEP DRAWN HELMET AND METHOD THEREFOR
Next Patent: METHODS AND MATERIAL COMPOSITIONS FOR SEALING A TRACT
Next Patent: METHODS AND MATERIAL COMPOSITIONS FOR SEALING A TRACT